CN110099685A - 溴结构域抑制剂 - Google Patents
溴结构域抑制剂 Download PDFInfo
- Publication number
- CN110099685A CN110099685A CN201780076154.0A CN201780076154A CN110099685A CN 110099685 A CN110099685 A CN 110099685A CN 201780076154 A CN201780076154 A CN 201780076154A CN 110099685 A CN110099685 A CN 110099685A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- polymer
- methylsulfonylphenyl
- cyclopropylmethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410756P | 2016-10-20 | 2016-10-20 | |
| US62/410,756 | 2016-10-20 | ||
| PCT/US2017/057439 WO2018075796A1 (en) | 2016-10-20 | 2017-10-19 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110099685A true CN110099685A (zh) | 2019-08-06 |
Family
ID=62019669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780076154.0A Pending CN110099685A (zh) | 2016-10-20 | 2017-10-19 | 溴结构域抑制剂 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3528810A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7129973B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110099685A (cg-RX-API-DMAC7.html) |
| AR (1) | AR109859A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017345468B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201821062A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018075796A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
| AU2019309693B2 (en) * | 2018-07-23 | 2023-03-16 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208814A1 (en) * | 2009-11-05 | 2012-08-16 | Emmanuel Hubert Demont | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors |
| CN105732624A (zh) * | 2016-01-28 | 2016-07-06 | 中国药科大学 | 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途 |
| CN105828820A (zh) * | 2013-10-18 | 2016-08-03 | 赛尔基因昆蒂赛尔研究公司 | 布罗莫结构域抑制剂 |
| CN105873577A (zh) * | 2013-08-30 | 2016-08-17 | 西奈山伊坎医学院 | 环插烯酰胺作为溴结构域抑制剂 |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| TW201642860A (zh) * | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | 布羅莫結構域抑制劑 |
-
2017
- 2017-10-19 CN CN201780076154.0A patent/CN110099685A/zh active Pending
- 2017-10-19 WO PCT/US2017/057439 patent/WO2018075796A1/en not_active Ceased
- 2017-10-19 AU AU2017345468A patent/AU2017345468B2/en not_active Ceased
- 2017-10-19 JP JP2019521064A patent/JP7129973B2/ja not_active Expired - Fee Related
- 2017-10-19 EP EP17862619.8A patent/EP3528810A4/en not_active Withdrawn
- 2017-10-20 AR ARP170102935A patent/AR109859A1/es unknown
- 2017-10-20 TW TW106136093A patent/TW201821062A/zh unknown
-
2022
- 2022-04-14 JP JP2022066855A patent/JP2022095897A/ja not_active Ceased
-
2024
- 2024-02-15 JP JP2024021416A patent/JP2024056905A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208814A1 (en) * | 2009-11-05 | 2012-08-16 | Emmanuel Hubert Demont | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| CN105873577A (zh) * | 2013-08-30 | 2016-08-17 | 西奈山伊坎医学院 | 环插烯酰胺作为溴结构域抑制剂 |
| CN105828820A (zh) * | 2013-10-18 | 2016-08-03 | 赛尔基因昆蒂赛尔研究公司 | 布罗莫结构域抑制剂 |
| CN105732624A (zh) * | 2016-01-28 | 2016-07-06 | 中国药科大学 | 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201821062A (zh) | 2018-06-16 |
| EP3528810A4 (en) | 2020-06-17 |
| AU2017345468B2 (en) | 2022-06-02 |
| WO2018075796A1 (en) | 2018-04-26 |
| JP2024056905A (ja) | 2024-04-23 |
| EP3528810A1 (en) | 2019-08-28 |
| AU2017345468A1 (en) | 2019-06-06 |
| AR109859A1 (es) | 2019-01-30 |
| JP7129973B2 (ja) | 2022-09-02 |
| JP2022095897A (ja) | 2022-06-28 |
| JP2019535671A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2983446C (en) | Bromodomain inhibitor | |
| CN105037355B (zh) | Wnt信号传导途径的吲唑抑制剂及其治疗用途 | |
| CN113226302B (zh) | 用于治疗或预防痛风或高尿酸血症的化合物的晶型 | |
| JP2024056905A (ja) | ブロモドメイン阻害剤 | |
| CN103842350B (zh) | 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用 | |
| US20230301983A1 (en) | Bromodomain inhibitor | |
| WO2023098872A1 (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
| CN106963766B (zh) | 一种氮杂螺酮类药物组合物及其制备方法 | |
| JP2020532522A (ja) | 感覚有毛細胞死を予防または処置するための化合物の結晶形態 | |
| CN101830911B (zh) | 一类噻吩并吡啶衍生物、其制备方法和用途 | |
| CA3121913C (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
| CN106916168B (zh) | 一种治疗重症胰腺炎的化合物及其制备方法 | |
| CN116492363A (zh) | 新的核苷氨基磷酸脂化合物的组合物及其制备方法 | |
| HK40056574B (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
| HK40056574A (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
| HK40032224A (en) | Crystalline forms of compounds for preventing or treating sensory hair cell death |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190806 |